241 related articles for article (PubMed ID: 34460179)
21. Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US.
Insinga RP; Vanness DJ; Feliciano JL; Vandormael K; Traore S; Burke T
J Med Econ; 2018 Dec; 21(12):1191-1205. PubMed ID: 30188231
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of immune checkpoint inhibitors in the treatment of non-small-cell lung cancer as a second line in Taiwan.
Leung JH; Chang CW; Chan AL; Lang HC
Future Oncol; 2022 Mar; 18(7):859-870. PubMed ID: 35105168
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
Wu B; Chen H; Shen J; Ye M
Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
[TBL] [Abstract][Full Text] [Related]
24. Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal.
Dickson R; Bagust A; Boland A; Blundell M; Davis H; Dundar Y; Hockenhull J; Martin Saborido C; Oyee J; Ramani VS
Pharmacoeconomics; 2011 Dec; 29(12):1051-62. PubMed ID: 21967156
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France.
Marine S; Stéphane R; Nicolas P; Felizzi F; Paracha N; Benjamin M; Perol M
J Med Econ; 2020 May; 23(5):464-473. PubMed ID: 31951770
[No Abstract] [Full Text] [Related]
26. Cost-effectiveness of nivolumab monotherapy in the third-line treatment of small cell lung cancer.
Smare C; Dave K; Juarez-Garcia A; Abraham P; Penrod JR; Camidge DR; Yuan Y
J Med Econ; 2021; 24(1):1124-1133. PubMed ID: 34465261
[TBL] [Abstract][Full Text] [Related]
27. First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis.
Wan X; Luo X; Tan C; Zeng X; Zhang Y; Peng L
Cancer; 2019 Oct; 125(20):3526-3534. PubMed ID: 31287562
[TBL] [Abstract][Full Text] [Related]
28. Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50.
Kuznik A; Smare C; Chen CI; Venkatachalam M; Keeping S; Atsou K; Xu Y; Wilson F; Guyot P; Chan K; Glowienka E; Konidaris G
Value Health; 2022 Feb; 25(2):203-214. PubMed ID: 35094793
[TBL] [Abstract][Full Text] [Related]
29. A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing.
Matter-Walstra K; Schwenkglenks M; Aebi S; Dedes K; Diebold J; Pietrini M; Klingbiel D; von Moos R; Gautschi O;
J Thorac Oncol; 2016 Nov; 11(11):1846-1855. PubMed ID: 27311996
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness analysis of nivolumab-chemotherapy as first-line therapy for locally advanced/metastatic gastric cancer: a United States payer perspective.
Marupuru S; Arku D; Axon DR; Villa-Zapata L; Yaghoubi M; Slack MK; Warholak T
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):831-841. PubMed ID: 37243493
[TBL] [Abstract][Full Text] [Related]
31. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R
Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301
[TBL] [Abstract][Full Text] [Related]
32. A comparison of mixture cure fraction models to traditional parametric survival models in estimation of the cost-effectiveness of nivolumab for relapsed small cell lung cancer.
Roth JA; Yuan Y; Othus M; Danese M; Wagner S; Penrod JR; Ramsey SD
J Med Econ; 2021; 24(1):79-86. PubMed ID: 33334176
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer.
Aziz MIA; Tan LE; Tan WHG; Toh CK; Loke LPY; Pearce F; Ng K
J Med Econ; 2020 Sep; 23(9):952-960. PubMed ID: 32462958
[No Abstract] [Full Text] [Related]
34. Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model.
Zhao M; Shao T; Chi Z; Tang W
Front Public Health; 2023; 11():1051484. PubMed ID: 36908446
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA.
Zeng X; Wan X; Peng L; Peng Y; Ma F; Liu Q; Tan C
BMJ Open; 2019 Dec; 9(12):e031019. PubMed ID: 31831534
[TBL] [Abstract][Full Text] [Related]
36. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States.
Haddad R; Cohen EEW; Venkatachalam M; Young K; Singh P; Shaw JW; Korytowsky B; Abraham P; Harrington KJ
J Med Econ; 2020 May; 23(5):442-447. PubMed ID: 31928375
[No Abstract] [Full Text] [Related]
38. Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States.
Criss SD; Mooradian MJ; Watson TR; Gainor JF; Reynolds KL; Kong CY
JAMA Netw Open; 2019 Sep; 2(9):e1911952. PubMed ID: 31553470
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of second-line nivolumab for platinum-treated advanced non-small-cell lung cancer.
Zhang L; Zeng X; Cai H; Li N; Liu M; Qiu L; Zheng B
J Comp Eff Res; 2020 Dec; 9(18):1301-1309. PubMed ID: 33325265
[No Abstract] [Full Text] [Related]
40. First-Line Atezolizumab for Metastatic NSCLC with High PD-L1 Expression: A United States-Based Cost-Effectiveness Analysis.
Peng Y; Zeng X; Peng L; Liu Q; Yi L; Luo X; Li S; Wang L; Qin S; Wan X; Tan C
Adv Ther; 2021 May; 38(5):2447-2457. PubMed ID: 33821431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]